{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline states \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n2. **Different management plan** - Adjust delivery timing based on peak bile acid levels, with earlier delivery (36–37 weeks) only if bile acids ≥100 µmol/L.  \n   Reason: The guideline recommends \"Active management with planned early birth is recommended for women with ICP to reduce the risk of adverse outcomes,\" but emphasizes individualization based on bile acid levels. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n3. **Improved patient advice** - Clarify that CTG and ultrasound do not predict or prevent stillbirth in ICP, and emphasize fetal movement monitoring instead.  \n   Reason: The guideline states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods to establish a reference for comparison.  \n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n2. **Improved patient advice** - Counsel the patient about the increased risk of gestational diabetes and pre-eclampsia with ICP.  \n   Reason: The guideline notes that women with ICP have a higher chance of developing these conditions and should be monitored. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n3. **Different management plan** - Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.  \n   Reason: The guideline states \"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n### Less Important Recommendations\n1. **Additional information needed** - Consider discussing severe or atypical cases with a hepatologist if bile acids are very high or presentation is unusual.  \n   Reason: The guideline suggests specialist hepatology advice for severe, very early, or atypical presentations. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n2. **Improved patient advice** - Provide information on ICP recurrence risk in future pregnancies and the need for baseline testing.  \n   Reason: The guideline notes that women with a history of ICP should have baseline tests in subsequent pregnancies. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n### Unimportant Recommendations\n1. **Improved patient advice** - Offer links to ICP support groups (e.g., ICP Support, RCOG) for additional patient education.  \n   Reason: The guideline lists useful links for patient support, though this is not critical for clinical management. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \n\n### Summary of Key Adjustments Needed:\n- **De-emphasize UDCA** unless strictly for symptom relief.  \n- **Tailor delivery timing** strictly to bile acid levels (≥100 µmol/L).  \n- **Focus on fetal movement monitoring** rather than reliance on CTG/ultrasound.  \n- **Counsel on associated risks** (gestational diabetes, pre-eclampsia).  \n- **Avoid unnecessary interventions** (routine vitamin K, excessive testing).  \n\nThese changes align the note with the guideline’s emphasis on evidence-based, risk-stratified management.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 54 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 4098,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if pruritus is severe, as it does not improve perinatal outcomes.\",\n      \"context\": \"Guideline recommends against routine UDCA use for perinatal outcomes\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Aim for delivery at 36–37 weeks if bile acids <100 µmol/L.\",\n      \"suggestedText\": \"Plan delivery at 36–37 weeks only if bile acids ≥100 µmol/L, otherwise continue monitoring.\",\n      \"context\": \"Delivery timing should be strictly based on bile acid thresholds\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Emphasize fetal movement monitoring over CTG/ultrasound as primary surveillance method.\",\n      \"context\": \"CTG and ultrasound do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for future reference.\",\n      \"context\": \"Baseline measurements help establish normal levels for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no discussion of gestational diabetes/pre-eclampsia risks\",\n      \"suggestedText\": \"Counsel patient about increased risks of gestational diabetes and pre-eclampsia with ICP.\",\n      \"context\": \"Women with ICP have higher chance of developing these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Gap: no discussion of vitamin K use\",\n      \"suggestedText\": \"Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.\",\n      \"context\": \"Guideline recommends against routine vitamin K treatment\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Gap: no discussion of ICP recurrence risk\",\n      \"suggestedText\": \"Counsel patient about ICP recurrence risk in future pregnancies and need for baseline testing.\",\n      \"context\": \"Women with history of ICP should have baseline tests in subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-13T17-15-31",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \\n   Reason: The guideline states \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\\\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n2. **Different management plan** - Adjust delivery timing based on peak bile acid levels, with earlier delivery (36–37 weeks) only if bile acids ≥100 µmol/L.  \\n   Reason: The guideline recommends \\\"Active management with planned early birth is recommended for women with ICP to reduce the risk of adverse outcomes,\\\" but emphasizes individualization based on bile acid levels. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n3. **Improved patient advice** - Clarify that CTG and ultrasound do not predict or prevent stillbirth in ICP, and emphasize fetal movement monitoring instead.  \\n   Reason: The guideline states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\\\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods to establish a reference for comparison.  \\n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n2. **Improved patient advice** - Counsel the patient about the increased risk of gestational diabetes and pre-eclampsia with ICP.  \\n   Reason: The guideline notes that women with ICP have a higher chance of developing these conditions and should be monitored. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n3. **Different management plan** - Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.  \\n   Reason: The guideline states \\\"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\\\" (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Consider discussing severe or atypical cases with a hepatologist if bile acids are very high or presentation is unusual.  \\n   Reason: The guideline suggests specialist hepatology advice for severe, very early, or atypical presentations. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n2. **Improved patient advice** - Provide information on ICP recurrence risk in future pregnancies and the need for baseline testing.  \\n   Reason: The guideline notes that women with a history of ICP should have baseline tests in subsequent pregnancies. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n### Unimportant Recommendations\\n1. **Improved patient advice** - Offer links to ICP support groups (e.g., ICP Support, RCOG) for additional patient education.  \\n   Reason: The guideline lists useful links for patient support, though this is not critical for clinical management. (bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf)  \\n\\n### Summary of Key Adjustments Needed:\\n- **De-emphasize UDCA** unless strictly for symptom relief.  \\n- **Tailor delivery timing** strictly to bile acid levels (≥100 µmol/L).  \\n- **Focus on fetal movement monitoring** rather than reliance on CTG/ultrasound.  \\n- **Counsel on associated risks** (gestational diabetes, pre-eclampsia).  \\n- **Avoid unnecessary interventions** (routine vitamin K, excessive testing).  \\n\\nThese changes align the note with the guideline’s emphasis on evidence-based, risk-stratified management.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 54 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 4098,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if pruritus is severe, as it does not improve perinatal outcomes.\",\n      \"context\": \"Guideline recommends against routine UDCA use for perinatal outcomes\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Aim for delivery at 36–37 weeks if bile acids <100 µmol/L.\",\n      \"suggestedText\": \"Plan delivery at 36–37 weeks only if bile acids ≥100 µmol/L, otherwise continue monitoring.\",\n      \"context\": \"Delivery timing should be strictly based on bile acid thresholds\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Emphasize fetal movement monitoring over CTG/ultrasound as primary surveillance method.\",\n      \"context\": \"CTG and ultrasound do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for future reference.\",\n      \"context\": \"Baseline measurements help establish normal levels for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no discussion of gestational diabetes/pre-eclampsia risks\",\n      \"suggestedText\": \"Counsel patient about increased risks of gestational diabetes and pre-eclampsia with ICP.\",\n      \"context\": \"Women with ICP have higher chance of developing these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Gap: no discussion of vitamin K use\",\n      \"suggestedText\": \"Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.\",\n      \"context\": \"Guideline recommends against routine vitamin K treatment\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Gap: no discussion of ICP recurrence risk\",\n      \"suggestedText\": \"Counsel patient about ICP recurrence risk in future pregnancies and need for baseline testing.\",\n      \"context\": \"Women with history of ICP should have baseline tests in subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 2089\nCompletion tokens: 820\nTotal tokens: 2909\nEstimated cost: $0.001455",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 2089,
    "completion_tokens": 820,
    "total_tokens": 2909,
    "estimated_cost_usd": 0.0014545
  }
}